Navigation Links
Pharmacyclics to Present at Bank of America Merrill Lynch Healthcare Conference and MDB Bright Lights Conference
Date:5/6/2010

SUNNYVALE, Calif., May 6 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated diseases and cancer, today announced presentations at two investor conferences in the coming week.  David Loury PhD, Chief Scientific Officer, will be presenting at the MDB Bright Lights Conference in San Francisco, CA at the Palace Hotel on Tuesday, May 11 at 4:00 P.M. PDT.  Joseph Buggy PhD, Vice President of Research, will be presenting at the Bank of America Merrill Lynch Healthcare Conference in New York, NY at the Grand Hyatt on Wednesday, May 12 at 4:20 P.M. EDT/1:20 P.M. PDT.

There will be a live webcast of the Bank of America Merrill Lynch conference presentation, which will be accessible through a link posted on the investor relations/events & webcasts section of the PCYC website, please go to http://ir.pharmacyclics.com/events.cfm

About Pharmacyclics

Pharmacyclics(R) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of immune mediated disease and cancer. Our mission and goal are worth repeating: to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs. To identify promising product candidates based on exceptional scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate. We exist to make a difference for the better and these are important times to do just that.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmacyclics to Present at the RBC Capital Markets Healthcare Investor Conference
2. Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results
3. Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7
4. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
5. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
6. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
7. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
8. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
9. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
10. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
11. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... MELBOURNE, Australia , Feb. 21, 2017  IBM (NYSE: ... IBM Watson,s ability to detect abnormalities of the eye,s retina. ... trained a research version of Watson to recognize abnormalities in ... insights and speed in their early identification of patients who ... glaucoma, a leading cause of blindness in the developed world. ...
(Date:2/21/2017)... Medical Oxygen Concentrators Market: Overview ... Medical oxygen concentrators are used by patients ... having low level of oxygen in their blood ... are to be used only with prescription and ... concentrators work either on rechargeable lithium batteries or ...
(Date:2/21/2017)...   BeyondSpring Pharmaceuticals , a clinical stage ... immuno-oncology cancer therapies, today announced that the Company,s ... 2 trial of BeyondSpring,s innovative lead asset, ... lung cancer (NSCLC) with Docetaxel has been selected ... Immuno-Oncology Symposium in Orlando, Fla. ...
Breaking Medicine Technology:
(Date:2/21/2017)... ... February 21, 2017 , ... Individuals who have been diagnosed ... surgery, treatment, therapy and management. Regular exercise in proper environments has been shown ... their diseases. On February 23, 2017, 1:00-2:00 p.m. E.S.T., a dynamic HydroWorx ...
(Date:2/21/2017)... NJ (PRWEB) , ... February 21, 2017 , ... ... research and conference coverage in veterinary medicine, will be launching its first bi-monthly ... animal health and medicine, business and practice management, and One Health. , ...
(Date:2/21/2017)... ... 2017 , ... Atlanta-based Jvion, the leading cognitive clinical science ... practice. Predixion, which raised $42M+ to date, received $20M in its third ... Ventures, and Software AG , will bring top industry talent and an impressive ...
(Date:2/21/2017)... ... February 21, 2017 , ... A February 6 article on Healio ... It found that the treatments have led to significant improvements in weight loss and ... efforts. It also noted very few problematic results relating to the treatment. Beverly Hills ...
(Date:2/20/2017)... Ill. (PRWEB) , ... February 20, 2017 , ... ... to reduce the rate at which women are called back for additional examinations ... journal Radiology . , In 2011, the U.S. Food and Drug Administration ...
Breaking Medicine News(10 mins):